Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2021 Jan 26:2021.01.25.428137. [Version 2] doi: 10.1101/2021.01.25.428137

PMC7852271.2; 2021 Jan 26
PMC7852271.3; 2021 Feb 12

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Fig. 2 | — a, Footprints of neutralizing mAbs on the RBD. Left panel, top view of SARS-COV-2 spike with one RBD in the “up” conformation (pdb: 6zgg). RBD and NTD are colored green and peach, respectively. The positions of ‘inner’ and ‘outer’ sides are indicated on the “up” RBD with the ACE2-binding site colored yellow. The three panels to the right show the antibody footprints on RBD. b, Neutralization of UKΔ8, SAΔ9, and WT pseudoviruses by select RBD mAbs. c, Fold-change in IC50 of neutralizing mAbs against UKΔ8 and SAΔ9, as well as single-mutation pseudoviruses, relative to WT. MPI↓ denotes that maximum percent inhibition is substantially reduced, confounding IC50 calculations. d, Neutralization of UKΔ8, SAΔ9, and WT pseudoviruses by NTD-directed mAbs, the footprints of which are delineated by the color tracings in the insert. e, Changes in neutralization IC50 of authorized or investigational therapeutic mAbs against UKΔ8 and SAΔ9. Data in b and d are mean ± SEM of technical triplicates, and represent one of two independent experiments.

Fig. 2 | — a, Footprints of neutralizing mAbs on the RBD. Left panel, top view of SARS-COV-2 spike with one RBD in the “up” conformation (pdb: 6zgg). RBD and NTD are colored green and peach, respectively. The positions of ‘inner’ and ‘outer’ sides are indicated on the “up” RBD with the ACE2-binding site colored yellow. The three panels to the right show the antibody footprints on RBD. b, Neutralization of UKΔ8, SAΔ9, and WT pseudoviruses by select RBD mAbs. c, Fold-change in IC50 of neutralizing mAbs against UKΔ8 and SAΔ9, as well as single-mutation pseudoviruses, relative to WT. MPI↓ denotes that maximum percent inhibition is substantially reduced, confounding IC50 calculations. d, Neutralization of UKΔ8, SAΔ9, and WT pseudoviruses by NTD-directed mAbs, the footprints of which are delineated by the color tracings in the insert. e, Changes in neutralization IC50 of authorized or investigational therapeutic mAbs against UKΔ8 and SAΔ9. Data in b and d are mean ± SEM of technical triplicates, and represent one of two independent experiments.